贝达药业：公司对武汉禾元生物科技股份有限公司的投资计入其他权益工具投资科目核算

Group 1 - The company, BeiGene, stated that its investment in Wuhan Heyuan Biotechnology Co., Ltd. is accounted for under other equity instruments, and the fair value changes are recorded in other comprehensive income, which does not affect the company's net profit [1]